Cambridge Healthtech Institute’s 2nd Annual

Preclinical and Translational Immuno-Oncology
( 癌症免疫疗法的临床前研究与转译医学研究 )

Advanced Immuno-Oncology Models and How They Translate to the Clinic



Modeling the immune system and its response to cancer sets a particularly difficult challenge. The different cell types required, heterogeneity of tumours and the signaling pathways involved mean that multiple advanced models are required to justify clinical trials. But which ones do you choose and how do they relate to the clinic? At the Preclinical and Translational Immuno-Oncology conference, we will delve deeper into the advantages and disadvantages of each model and the strategies employed to help translate positive results to clinical trials. Models to be discussed include humanized mice models, syngeneic and xenograph models, 3D models and organoids, plus many more.

Preliminary Agenda


TNFR2 Antagonism: Specificity for the TME and the TNFR2 Oncogenes

Denise Faustman, MD, PhD, Director of Immunobiology, Harvard Medical School/Massachusetts General Hospital

Stress-Induced Post-Translational Modifications (siPTMs) as Targets for Cancer Vaccines

Lindy Durrant, PhD, Professor of Cancer Immunotherapy, University of Nottingham


Combinatorial Approaches to Enhance Bispecific Anti-Tumor Efficacy

Eric Smith, PhD, Senior Director, Bispecific Antibodies, Regeneron Pharmaceuticals

DNA-Based Nanobody Delivery

Carlo Boutton, PhD, Head Nanobody Explorative Technologies, Ablynx - Sanofi

Tissue Distribution, Elimination, and Target Engagement of Biologics-Going from Mice to Men and from in vivo to in silico

Armin Sepp, PhD, Scientific Leader and GSK Fellow, IVIVT, DMPK Modeling, GlaxoSmithKline


In vitro/Ex vivo 3D Models to Address the Immune Tumor Microenvironment

Catarina Brito, PhD, Lab Head, Animal Cell Technology Unit, iBET

Applying Genetically Engineered Mouse Models of Cancer to Drug Discovery Research

Elizabeth Hardaker, PhD, Associate Director & Head, Oncology In Vivo Pharmacology Group, AstraZeneca

How Can Cutting-Edge Preclinical Models Help Rational Cancer Immuno-Therapy Design?

Sara Colombetti, PhD, Head of Oncology Discovery Pharmacology, Research and Early Development (pRED), Roche Pharma

* 活动内容有可能不事先告知作更动及调整。